Article
Directed evolution of liver-detargeted AAV vectors for systemic gene delivery to skeletal muscle and heart
21 Aug 2025
Abstract excerpt
Adeno-associated virus (AAV) gene therapies that require systemic administration of high vector doses are associated with hepatotoxicity risk, given the liver tropism of most AAV vectors. We combined screening of natural serotypes, targeted mutagenesis, and directed evolution to identify liver-detargeted muscle-tropic capsids. We found that AAVhu.32 is liver-detargeted compared to AAV9, and AAV5 exhibits high...
Topics
Join the communities discussing this publication.
